Learn about side effects, uses, and more for Libtayo (cemiplimab-rwlc), which is a prescription drug that treats certain kinds of skin and lung cancer in adults.

About the Phase 3 Trial in Advanced NSCLC EMPOWER-Lung 1 was an open-label, randomized, multi-center Phase 3 trial designed to investigate Libtayo monotherapy compared to platinum-doublet ...

Paris and Tarrytown, NY – May 5, 2020 - Topline data for a pivotal, single-arm, open-label trial for Sanofi and Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) in patients with advanced ...

Regeneron and Sanofi also expect to submit regulatory applications for a Libtayo label expansion in the European Union by the end of this year, which suggests a regulatory approval could come next ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

EMPOWER-Lung 1 was an open-label, randomized, multi-center Phase 3 trial designed to investigate Libtayo monotherapy compared to platinum-doublet chemotherapy as first-line treatment in patients ...

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with ...

The number on Libtayo’s label, which counts all randomized participants, has the death risk reduction at 32%. RELATED: Merck's PD-1 king has two sets of phase 3 monotherapy data.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.

Libtayo is approved for the first-line treatment of patients with metastatic or locally advanced NSCLC with high PD-L1 expression (TPS ≥50%).

Libtayo is now approved for three advanced cancers in the European Union, following the EC’s concurrent approval of Libtayo for the first-line treatment of adult patients with advanced non-small ...

Regeneron and Sanofi also expect to submit regulatory applications for a Libtayo label expansion in the European Union by the end of this year, which suggests a regulatory approval could come next ...